While there is an ongoing update in psychiatric classification (e.g. DSM IV, IV TR, DSM 5 etc. and ICD 8, 9, 10 etc.). The nomenclature for psychotropic has not been substantially revised in the last 60 years (!).This app is aimed to fill this gap by incorporating contemporary data which has been gathered in neuroscience to the nomenclature. The Neuroscience based Nomenclature (NbN) is 4 axis pharmacological driven nomenclature, which reflects our current knowledge and organized in a clinician's friendly matter. Axis 1: pharmacological target and mode of action – Brings state of the art knowledge on targeted neurotransmitter / molecule / system being modified + relevant mode / mechanism of actionAxis 2: approved indications – Is based on the recommendations of major regulatory bodies (e.g. FDA, EMA, etc.)Axis 3: efficacy and side effects – Together with the “practical notes”, summarizes the "collective clinical wisdom" of the committeeAxis 4: neurobiology – Is derived from empirical dataNbN, which currently encompasses 108 compounds, includes all the widely used psychotropic. 1. Medication Included.In principle, medication with approved CNS indications are included. In this app you will find the medications that we were aware of. The taskforce welcome proposals to include medications that for one reason or another were omitted. (Please check our website, www.ecnp.eu/nomenclature).1a. Fixed combination of medication.The taskforce decided not to include them. This decision reflects the critical view of the taskforce on this type of practice.2. Inclusion criteria for the efficacy section.Positive single, large, RCT and/or "heavy solid weight" clinical data.3. Inclusion criteria for the side effects section.Only prevalent or life-threatening side effects were included.4. The committee note (Practical Note)Presented in a nutshellclinical knowledge that has been "filtered" through the taskforce clinical "sieve".5. Neurobiology.This axis is focused on the biology. It is divided into preclinical and clinical sections, with the emphasis on the latter.6. Affinity.Included only were it is clinically relevant and if human data is available. Please note that it is incomplete in this edition but we intend to complete it for the next edition.7. Uptake Inhibitors.Figures for the SERT/NET or NET/SERT uptake inhibition have been taken from studies of uptake inhibition which use human transporters. If there is more than one study we have taken a mean. If there are only rat transporter studies, we have used these in the same way but added (rat) to the description. This app has been developed by the taskforce of 5 well respected international organizations:ECNP - European College of NeuropsychopharmacologyACNP - American College of NeuropsychopharmacologyAsCNP - Asian College of NeuropsychopharmacologyCINP - International College of NeuropsychopharmacologyIUPHAR - International Union of Basic and Clinical Pharmacology The taskforce did its best to ensure a balanced, cutting edge, scientific based document. Although the product that you see is the result of 6 years work, we do realize that it is not perfect and that there are mistakes and significant omissions. We rely on you to help us to improve this imperfect, this beta 1 version (draft if you wish) of this app. Integral part of the NbN and a key for its development and success is the feedback element. The taskforce has put forward a Wikipedia kind of approach (emphasizing the importance and strength of the clinicians / pharmacologist's "collective wisdom") as one of the corner stones. Accordingly, we will more than welcome any feedback and promise to take it into account while preparing the 2015 edition.